Study to Determine the Effectiveness of GSK1120212 in BRAF Mutation-positive Melanoma Previously Treated With or Without a BRAF Inhibitor

NCT01037127 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

97

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer

Interventions

DRUG: GSK1120212

Sponsor

GlaxoSmithKline